For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Research and development | 53,684 | 57,067* | 27,094 | |
| General and administrative | 10,819 | 17,522* | 4,404 | |
| Total operating expenses | 64,503 | 74,589 | 31,498 | |
| Loss from operations | -64,503 | -74,589* | -31,498 | |
| Interest income | 2,472 | 871* | 1,549 | |
| Other income, net | 1,363 | 820* | 531 | |
| Total other income, net | - | 1,691* | 2,080 | |
| Net loss | -60,668 | -72,898 | -29,418 | |
| Basic EPS | -1.34 | -4.399 | -37.18 | |
| Diluted EPS | -1.34 | -4.399 | -37.18 | |
| Basic Average Shares | 45,276,763 | 16,570,355 | 791,127 | |
| Diluted Average Shares | 45,276,763 | 16,570,355 | 791,127 | |
MapLight Therapeutics, Inc. (MPLT)
MapLight Therapeutics, Inc. (MPLT)